AAA

ADVICENNE

No trades
See on Supercharts
Next report date
Report period
H1 2024
EPS estimate
Revenue estimate
Market capitalization
‪20.27 M‬EUR
−0.664EUR
‪−7.03 M‬EUR
‪4.46 M‬EUR
‪6.13 M‬
Beta (1Y)
0.08

About ADVICENNE

CEO
Didier Laurens
Headquarters
Paris
Founded
2007
ISIN
FR0013296746
FIGI
BBG00JB78ZQ6
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. It develops treatment for both adults and kids. The company was founded in 2007 by Luc-André Granier and Caroline Roussel-Maupetit and is headquartered in Paris, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALDVI is 1.648 EUR — it has increased by 1.10% in the past 24 hours. Watch ADVICENNE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange ADVICENNE stocks are traded under the ticker ALDVI.
ADVICENNE is going to release the next earnings report on Sep 18, 2024. Keep track of upcoming events with our Earnings Calendar.
ALDVI stock is 2.96% volatile and has beta coefficient of 0.08. Track ADVICENNE stock price on the chart and check out the list of the most volatile stocks — is ADVICENNE there?
Yes, you can track ADVICENNE financials in yearly and quarterly reports right on TradingView.
ALDVI stock has fallen by 3.63% compared to the previous week, the month change is a 36.62% fall, over the last year ADVICENNE has showed a 51.14% decrease.
ALDVI net income for the last quarter is ‪−3.30 M‬ EUR, while the quarter before that showed ‪−3.73 M‬ EUR of net income which accounts for 11.70% change. Track more ADVICENNE financial stats to get the full picture.
Today ADVICENNE has the market capitalization of ‪20.25 M‬, it has decreased by 2.63% over the last week.
No, ALDVI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALDVI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADVICENNE stock right from TradingView charts — choose your broker and connect to your account.
ALDVI reached its all-time high on Feb 16, 2021 with the price of 15.956 EUR, and its all-time low was 1.100 EUR and was reached on Mar 4, 2024. View more price dynamics on ALDVI chart.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADVICENNE technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADVICENNE stock shows the sell signal. See more of ADVICENNE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ADVICENNE future price: according to them, ALDVI price has a max estimate of 7.30 EUR and a min estimate of 6.50 EUR. Watch ALDVI chart and read a more detailed ADVICENNE stock forecast: see what analysts think of ADVICENNE and suggest that you do with its stocks.